Application of substance for detecting XCL2 gene expression in preparation of product for detecting Parkinson's disease
Mapping the peripheral immune map of Parkinson's disease patients through scRNA-seq analysis, detecting gene expression of NK cells and other immune cell subpopulations, especially the JUN and XCL2 genes, solves the trauma risk and accuracy of Parkinson's disease diagnosis in the prior art sexual problems, achieving high specificity and high accuracy of early screening and diagnosis.
Patent Information
- Application Number
- CN202411202224.0
- Authority / Receiving Office
- CN · China
- Patent Type
- Applications(China)
- Current Assignee / Owner
- Filing Date
- 2024-08-29
- Publication Date
- 2024-11-26
- Estimated Expiration
- 2044-08-29
AI Technical Summary
The prior art relies on cerebrospinal fluid detection in the diagnosis of Parkinson's disease, has trauma risk and limited early diagnosis accuracy, and lacks an effective peripheral immune response map, which limits early screening and therapeutic interventions in the disease.
Mapping of peripheral immune profiles of Parkinson's disease patients and control groups by scRNA-seq analysis, detecting gene expression of NK cells and other immune cell subpopulations, especially JUN and XCL2 gene expression, to develop diagnostic markers for Parkinson's disease .
Provides high specificity and high accuracy early screening and diagnostic tools, and realizes the screening and diagnosis of Parkinson's disease through blood tests, overcomes the traumatic disorder of cerebrospinal fluid detection, and promotes the treatment strategies for early detection and early treatment of diseases. .
Smart Images

Figure BDA0005018114540000121 
Figure BDA0005018114540000131 
Figure BDA0005018114540000141
Abstract
Description
Technical Field
[0001] This specification relates to the field of neurodegenerative diseases, and in particular to a product for detecting human Parkinson's disease. Background Art
[0002] Parkinson's disease (PD) is a common neurodegenerative disease. The accumulation of intracellular protein inclusions, Lewy bodies (LB), is a pathological hallmark of both sporadic and familial Parkinson's disease. Due to the aging population, up to 12 million people are expected to develop Parkinson's disease in the next decade. Currently, the diagnosis of Parkinson's disease is entirely based on clinical observation, with limited accuracy and high misdiagnosis rate, which has long posed a huge challenge to clinical medicine. Increasing evidence shows that biomarkers have the potential to be used in the diagnosis of neurodegenerative diseases. Cerebrospinal fluid (CSF) biomarkers are used for the diagnosis of PD, including CSF Aβ1-42, total tau (T-tau), tau phosphorylated at threonine 181 (P-tau181), neurofilament light chain protein (NFL), cardiac fatty acid binding protein (HFABP) and alpha-synuclein. However, due to the risks of invasive surgery such as lumbar puncture, the application of these biomarkers in early clinical diagnosis and efficacy monitoring is limited.
[0003] Recent studies on various neurodegenerative diseases have shifted the focus from the central nervous system to the peripheral blood. Under physiological conditions, peripheral immune cells are difficult to detect in the central nervous system due to the presence of the blood-brain barrier (BBB). However, the pathological process of Parkinson's disease can disrupt the BBB, and the disruption of the BBB leads to increased infiltration of peripheral immune cells into the central nervous system, which has been identified as one of the major causes of Parkinson's disease. Recently, many studies have reported the relevance of peripheral immune responses in PD disease progression. It has been proposed that T cell responses associated with α-synuclein pathology in mouse PD models may impair the use of key areas of the central nervous system. In a recent study, NK cells were shown to be scavengers of α-syn, and systemic depletion of NK cells in preclinical PD mouse models exacerbated synuclein pathology. However, the construction of a peripheral immune response profile for PD progression is still lacking. A better understanding of the host immune response profile during PD is urgently needed to better design prognostic and diagnostic markers and provide appropriate therapeutic interventions for patients with severe disease manifestations. Summary of the invention
[0004] In order to solve the above technical problems, this application uses scRNA-seq analysis to draw the peripheral immune map of PD by analyzing PBMCs of patients with early PD, late PD and matched control groups. This application further expands the blood sample volume and clinically verifies the role of NK cells in many immune-related biological processes. In order to clarify the connection between the peripheral and central nervous systems, this application also uses human brain slices to detect the infiltration of NK cells into the motor cortex of the brain as the disease progresses.
[0005] The present application provides the use of a substance for detecting JUN and / or XCL2 gene expression in the preparation of a product for detecting Parkinson's disease.
[0006] The present application also provides a product for detecting Parkinson's disease, wherein the product comprises a substance for detecting the expression of JUN and / or XCL2 genes.
[0007] The beneficial effects brought by the present application include but are not limited to: 1. The expression of the markers provided by the present application for the detection, early screening or diagnosis of the progression of Parkinson's disease is positively correlated with the HY score of Parkinson's disease patients, and the expression is significantly increased in Parkinson's disease patients, with strong specificity and high accuracy; 2. The kit prepared by the markers provided by the present application and the detected substances thereof can realize the screening, diagnosis or prediction of Parkinson's disease through blood test, overcoming the technical obstacle of the prior art that only cerebrospinal fluid diagnosis can be performed during the asymptomatic period, greatly alleviating the suffering of patients, and promoting the treatment policy of early detection and early diagnosis and treatment of the disease, which is of great significance for the diagnosis, treatment and research of Parkinson's disease. BRIEF DESCRIPTION OF THE DRAWINGS
[0008] The present application will be further described in the form of exemplary embodiments, which will be described in detail with reference to the accompanying drawings. These embodiments are not restrictive, and include:
[0009] Figure 1 (A) Experimental workflow diagram for the study of cell clusters of PBMC populations of healthy controls and Parkinson's disease patients annotated according to ScRNA-seq as shown in some embodiments of the present application. (B) The number of cells in each sample obtained by 10×scRNA-seq before and after quality control. (C) UMAP projection of 12 different cell clusters. (D) The dot plot shows the average logCPM of the classic marker genes of the 12 cell clusters. (E) The UMAP diagram shows the distribution of 6 major cell types. CD4_T cells: clusters 06, 8; CD8_T cells: clusters 1, 4, 10; NK cells: cluster 2; monocytes: clusters 3, 7 and 9; B cells: cluster 5; GMP: cluster 11.
[0010] Figure 2The changes in gene expression in different cell subpopulations shown in some embodiments of the present application. (A) UMAP diagram shows the expression of classic marker genes of 6 cell subpopulations. (B) Heat map shows the differential gene expression of different cell types at different stages of PD. (C) The intersection of up-regulated or down-regulated differentially expressed genes in different cell subpopulations and PD pathway-related genes. (D) Cartoon flowchart shows that peripheral immune cells are closely related to PD.
[0011] Figure 3 The proportion changes of cell subtypes in PD progression according to some embodiments of the present application. (A) UMAP diagram shows the distribution of 6 major cell types in each sample. (B) Changes in major cell types in healthy controls, early and late PD patients. (CD) Bar graphs show the percentage changes of each cell subtype at different stages of PD.
[0012] Figure 4 The identification of differential cell subsets in human peripheral blood and brain during PD progression as shown in some embodiments of the present application. (AB) The scatter plots and bar graphs respectively detect the T cells (CD45 + CD3 + ), B cells (CD45 + CD3 - CD19 + ) and NK cells (CD45 + CD3 - / CD16 + CD56 +). (C) Bar graphs showing the correlation between the percentage of T cells, B cells, and NK cells in PD patients and the HY score of PD patients. (D-E) Immunofluorescence staining images and quantitative bar graphs showing the expression of NK cells in PBMCs of healthy controls (n=6), early (n=4-6), and late (n=5-6). Green indicates CD56 and CD16 positive cells. Blue indicates DAPI stained cell nuclei. Scale bar = 50 μm. Data are expressed as mean ± SD and analyzed by one-way ANOVA and Tukey's post hoc test. (FG) TH immunofluorescence staining and quantification of the amygdala and motor cortex of healthy controls (n=3) and late PD patients (n=5 sections from 2 patients). Green indicates TH positive cells. Blue indicates DAPI stained cell nuclei. Scale bar = 50 μm. Data are expressed as mean ± SD and analyzed by one-way ANOVA and Tukey's post hoc test. (HI) Immunofluorescence staining and quantification showing the expression of NK cells in the amygdala and motor cortex of brain sections from healthy controls (n=3) and advanced PD patients (n=5 sections from 2 patients). Green indicates CD56-positive cells. Blue indicates DAPI-stained cell nuclei. Scale bar = 50 μm. Data are presented as mean ± SD and analyzed by one-way ANOVA and Tukey's post hoc test. (J) Correlation analysis between the number of NK cells and the TH fluorescence intensity in the amygdala and motor cortex of advanced PD patients. *p<0.05, **p<0.01, ***p<0.001.
[0013] Figure 5Bioinformatics analysis of key genes in NK cells of PD patients according to some embodiments of the present application (A) Heat map shows the expression of upregulated DEGs in NK cells of healthy control group, early PD and late PD stages. (B) The intersection of three groups of fold change values. FC1 (fold change 1), early PD vs. healthy control group; FC2 (fold change 2), late PD vs. early PD; FC3 (fold change 3), late PD vs. healthy control group. (C) GO analysis of the intersection of key genes. (D) Volcano map shows the differential expression of key genes in NK cells. (E) Heat map shows the expression changes of key upregulated DEGs obtained by volcano map in healthy control group, early PD and late PD stages. (F) GO analysis of key upregulated DEGs in NK cells determined by volcano map. (G) Heat map shows the expression changes of downregulated DEGs in healthy control group, early PD and late PD stages. (H) The intersection of three groups of fold change values. FC1 (fold change 1), early PD vs. healthy control group; FC2 (fold change 2), late PD vs. early PD; FC3 (fold change 3), late PD vs. healthy control group. (I) GO analysis of key gene intersections. (J) KEGG enrichment analysis of key gene intersections.
[0014] Figure 6 (A) Screening of DEGs of NK cells according to the predictive performance of biomarkers for PD severity as shown in some embodiments of the present application. (B) Relative expression of NK cell-specific upregulated DEGs. Healthy control (n=13), PD group (n=36, CCL3; 31, NFKBIA; 35, JUN; 29, IER2; 25, IER2; 38, LY6E; 38, MT2A; 35, XCL2; 35, FOS; 35, IFITM3). (C) AUC values of JUN and XCL2 for predicting PD at different stages. (D) Expression of JUN in major cell subsets of PBMCs in healthy controls, early and late PD patients. (E) Expression of XCL2 in major cell subsets of PBMCs in healthy controls, early and late PD patients. (F) Correlation between JUN level and HY score in PD patients. (G) Correlation between XCL2 level and HY score in PD patients.
[0015] Figure 7(A) UMAP diagram showing the characteristics of NK cell subsets according to some embodiments of the present application. (B) Expression of marker genes used to identify 8 clusters of NK cells. (C) UMAP diagram showing the expression distribution of 8 cluster marker genes of NK cells. (D) Cell ratio of 8 clusters of NK cells at different stages of PD. (E) UMAP diagram showing the enrichment of XCL2 in each cluster. (F) Dot plot presents the expression of XCL2 in healthy controls, early and late C2 and C5. (G) GO enrichment and enrichment network analysis show that genes specifically upregulated in C2 and C5 are involved in enriched biological pathways.
[0016] Figure 8 The difference in XCL2 expression in B cells between the control group and PD2.0 patients and its diagnostic efficacy according to some embodiments of the present application. (A) Box scatter plot of XCL2 expression in B cells of patients in the control group (n=9) and PD2.0 group (n=11) is statistically significant (P<0.05). (B) The ROC curve of XCL2 diagnosis of PD2.0 was independently analyzed, showing an AUC of 0.7879, P<0.05.
[0017] Fig. 9 The difference in XCL2 expression in B cells between the control group and PD3.5 patients and its diagnostic efficacy according to some embodiments of the present application. (A) Box scatter plot of XCL2 expression in B cells of the control group (n=9) and PD3.5 group (n=4) patients, with statistical significance (P<0.05). (B) The ROC curve of XCL2 diagnosis of PD3.5 was independently analyzed, showing an AUC of 0.9722, P<0.05.
[0018] Fig.10 The difference in XCL2 expression in B cells between the control group and PD patients and its diagnostic efficacy according to some embodiments of the present application. (A) Box scatter plot of XCL2 expression in B cells of patients in the control group (n=9) and the PD group (n=15) is statistically significant (P<0.05). (B) The ROC curve of XCL2 for diagnosing PD was analyzed independently, showing an AUC of 0.8370, P<0.05. (C) The ROC curve of XCL2 for independent analysis, diagnosis of PD2.0, PD3.5 and PD patients was combined, showing that the AUCs were 0.7879, 0.9722, and 0.8370, respectively, and the P values were all less than 0.05.
[0019] Fig.11The difference in XCL2 expression in B cells of PD patients of different genders and its diagnostic efficacy according to some embodiments of the present application. (A) Box scatter plot of XCL2 expression in B cells of male group (n=17) and female group (n=15) patients, no statistical significance (P>0.05). (B) Independent analysis of the ROC curve of XCL2 in PD patients of different genders, showing AUC of 0.5686, P>0.05. DETAILED DESCRIPTION
[0020] In order to more clearly illustrate the technical solutions of the embodiments of this specification, the following is a brief introduction to the drawings required for the description of the embodiments. Obviously, the drawings described below are only some examples or embodiments of this specification. For ordinary technicians in this field, this specification can also be applied to other similar scenarios based on these drawings without creative work. Unless it is obvious from the language environment or otherwise explained, the same reference numerals in the figures represent the same structure or operation.
[0021] As shown in this specification and claims, unless the context clearly indicates an exception, the words "a", "an", "an" and / or "the" do not refer to the singular and may also include the plural. Generally speaking, the terms "comprise" and "include" only indicate the inclusion of the steps and elements that have been clearly identified, and these steps and elements do not constitute an exclusive list. The method or device may also include other steps or elements.
[0022] Flowcharts are used in this specification to illustrate the operations performed by the system according to the embodiments of this specification. It should be understood that the preceding or following operations are not necessarily performed precisely in order. Instead, the steps may be processed in reverse order or simultaneously. At the same time, other operations may also be added to these processes, or one or more operations may be removed from these processes.
[0023] Although the research focus of Parkinson's disease (PD) has shifted from the central neural system (CNS) to peripheral blood, there is still a large knowledge gap between the severity of PD and the peripheral blood immune response. This study aimed to map the peripheral blood immune landscape of peripheral blood mononuclear cells (PBMCs) in PD patients and healthy subjects using single-cell RNA sequencing (scRNA-seq) technology.
[0024] Recently, single-cell RNA sequencing (scRNA-seq) has emerged as an effective strategy to obtain a global view of disease-related changes at an unprecedented resolution. ScRNA-seq has the ability to identify disease-specific genetic variants to reveal disease-characteristic correlations in specific cell types, allowing the identification of multiple candidate biomarkers for diagnosis and prognosis in preclinical and clinical studies. In this application, differentially abundant cell subset profiles in peripheral blood mononuclear cells (PBMCs) of PD patients and healthy subjects and differentially expressed genes in NK cells were identified by scRNA-seq analysis. The indispensable functions of NK cells and NK cell-specific molecular biomarkers highlight the significance of peripheral immune responses in PD progression. The identification of possible pathogenic cell types and potential molecular biomarkers of Parkinson's disease reveals the feasibility of identifying disease biomarkers in specific cell types rather than whole blood, and will prompt researchers to develop more effective diagnostic tools for Parkinson's disease based on scRNA-seq results.
[0025] The present application provides the use of a substance for detecting JUN and / or XCL2 gene expression in the preparation of a product for detecting Parkinson's disease.
[0026] In some embodiments, the sample detected by the product can be peripheral blood. In some embodiments, further, the product can be used to detect the expression of JUN and / or XCL2 genes in NK cells of peripheral blood. In some embodiments, the Parkinson's disease detection product can be selected from a Parkinson's disease progression detection product or a Parkinson's disease risk assessment product. In some embodiments, the NK cells can be XCL2 + GZK - NK and XCL2 + GZK + NK cells.
[0027] In some embodiments, the XCL2 gene is specifically expressed in NK cell subtypes C2 and C5. In some embodiments, preferably, the XCL2 gene is only expressed in XCL2 + GZK - NK and XCL2 + GZK + Expressed in NK cells.
[0028] In some embodiments, the substance for detecting JUN or XCL2 gene expression comprises at least one of a primer pair, a probe or an antibody. In some embodiments, the nucleotide sequence of the primer pair for detecting JUN can be as shown in SEQ ID NO.11 and SEQ ID NO.12.
[0029] In some embodiments, the nucleotide sequences of the primer pair for detecting XCL2 may be shown as SEQ ID NO.19 and SEQ ID NO.20.
[0030] In some embodiments, the product can be any of a kit, a chip, a membrane strip, a protein array, a composition or a detection system. In some embodiments, preferably, the product can include one or more of a DNA polymerase, a deoxynucleotide (dNTP) mixture, a buffer solution, a positive control or a negative control.
[0031] In some embodiments, the product may further include a substance for detecting the expression of CCL3, FOS, IER2, IFITM3, LY6E, MT2A or NFKBIA genes. In some embodiments, the substance for detecting the expression of CCL3, FOS, IER2, IFITM3, LY6E, MT2A or NFKBIA genes may include at least one of a primer pair, a probe or an antibody.
[0032] In some embodiments, the method for using the product comprises the following steps: (1) extracting genomic DNA of NK cells in a peripheral blood sample to be tested; (2) performing an amplification reaction to obtain the expression level of at least one of the JUN or XCL2 genes in the sample to be tested; preferably, it also comprises detecting the expression level of at least one of the CCL3, FOS, IER2, IFITM3, LY6E, MT2A or NFKBIA genes; (3) judging the progression of Parkinson's disease in the patient providing the sample based on the gene expression level.
[0033] In some embodiments, the nucleotide sequences of the primer pair for detecting CCL3 may be as shown in SEQ ID NO.3 and SEQ ID NO.4.
[0034] In some embodiments, the nucleotide sequences of the primer pair for detecting FOS may be as shown in SEQ ID NO.5 and SEQ ID NO.6.
[0035] In some embodiments, the nucleotide sequences of the primer pair for detecting IER2 may be as shown in SEQ ID NO.7 and SEQ ID NO.8.
[0036] In some embodiments, the nucleotide sequences of the primer pairs for detecting IFITM3 may be as shown in SEQ ID NO.9 and SEQ ID NO.10.
[0037] In some embodiments, the nucleotide sequence of the primer pair for detecting LY6E may be as shown in SEQ ID NO.13 and SEQ ID NO.14.
[0038] In some embodiments, the nucleotide sequences of the primer pair for detecting MT2A may be as shown in SEQ ID NO.15 and SEQ ID NO.16.
[0039] In some embodiments, the nucleotide sequences of the primer pair for detecting NFKBIA may be as shown in SEQ ID NO.17 and SEQ ID NO.18.
[0040] In some embodiments, when the expression level of the human JUN or XCL2 gene corresponding to the peripheral blood sample to be tested is increased relative to that of a healthy person, preferably, when the expression level of at least one gene among CCL3, FOS, IER2, IFITM3, LY6E, MT2A or NFKBIA is increased relative to that of a healthy person, it is judged that the person corresponding to the peripheral blood sample to be tested suffers from Parkinson's disease, and / or, the risk of the person corresponding to the sample to be tested to develop Parkinson's disease is predicted to increase, and / or, the progression of Parkinson's disease in the patient providing the sample is judged. In some embodiments, the progression of Parkinson's disease can be divided into 5 stages according to the HY score, and the larger the number, the more severe the patient's clinical symptoms and the more serious the condition. Among them, 0 = no signs; 1.0 = unilateral disease; 1.5 = unilateral disease, and affecting the muscles of the central axis; 2.0 = bilateral disease, no damage to balance; 2.5 = mild bilateral disease, slightly poor postural reflexes, but can correct themselves; 3.0 = bilateral disease, postural balance disorder, positive pull test; 4.0 = severe disability, but can stand or walk by themselves; 5.0 = unable to get up, or living in a wheelchair. In some embodiments, when the expression level of the XCL2 gene in the human NK cells corresponding to the peripheral blood sample to be tested is increased relative to that of healthy people, it is judged that the person corresponding to the sample to be tested suffers from Parkinson's disease, and / or, the risk of Parkinson's disease in the person corresponding to the peripheral blood sample to be tested is predicted to be increased, and / or, the progression of Parkinson's disease in the patient providing the sample is judged. In some embodiments, preferably, when the human XCL2 corresponding to the peripheral blood sample to be tested is increased, the expression level of the XCL2 gene in the human NK cells corresponding to the peripheral blood sample to be tested is increased relative to that of healthy people, it is judged that the person corresponding to the sample to be tested suffers from Parkinson's disease, and / or, the risk of Parkinson's disease in the person corresponding to the peripheral blood sample to be tested is predicted to be increased, and / or, the progression of Parkinson's disease in the patient providing the sample is judged. In some embodiments, preferably, when the human XCL2 + GZK - NK and XCL2 + GZK + When the expression level of the XCL2 gene in NK cells increases relative to that of healthy people, it is judged that the person corresponding to the peripheral blood sample to be tested suffers from Parkinson's disease, and / or it is predicted that the risk of the person corresponding to the peripheral blood sample to be tested to develop Parkinson's disease is increased, and / or the progression of Parkinson's disease in the patient providing the sample is judged.
[0041] The present application also provides a product for detecting Parkinson's disease, wherein the product comprises a substance for detecting the expression of JUN and / or XCL2 genes.
[0042] In some embodiments, the sample detected by the product can be peripheral blood. In some embodiments, further, the product can be used to detect the expression of JUN and / or XCL2 genes in NK cells of peripheral blood. In some embodiments, the product for detecting Parkinson's disease can be selected from Parkinson's disease progression detection products or Parkinson's disease risk assessment products.
[0043] In some embodiments, the XCL2 gene is mainly expressed in NK cells. In some embodiments, preferably, the XCL2 gene is only expressed in XCL2 + GZK - NK and XCL2 + GZK + Expressed in NK cells.
[0044] In some embodiments, the substance for detecting JUN or XCL2 gene expression comprises at least one of a primer pair, a probe or an antibody.
[0045] In some embodiments, the nucleotide sequences of the primer pair for detecting JUN may be shown as SEQ ID NO.11 and SEQ ID NO.12.
[0046] In some embodiments, the nucleotide sequences of the primer pair for detecting XCL2 may be shown as SEQ ID NO.19 and SEQ ID NO.20.
[0047] In some embodiments, the product can be any of a kit, a chip, a membrane strip, a protein array, a composition or a detection system. In some embodiments, preferably, the product can include one or more of a DNA polymerase, a deoxynucleotide (dNTP) mixture, a buffer solution, a positive control or a negative control.
[0048] The term "kit" refers to a packaged collection of related components, such as one or more polynucleotides or compositions, and one or more related materials, such as a delivery device (e.g., a syringe), solvents, solutions, buffers, instructions, or desiccant.
[0049] The term "membrane strip" refers to a diagnostic tool that utilizes the principle of specific biomolecule recognition, fixes biomolecules such as antigens or antibodies on the membrane, specifically binds to the substances to be tested in the sample, and qualitatively or quantitatively analyzes the target substances in the sample through visualization or other signal detection methods.
[0050] The term "chip" generally refers to a microdevice that integrates biosensors and microfluidic technologies, which can perform a variety of operations such as sample preparation, reaction, and detection in biological, chemical, and medical analysis processes at the microscopic level to achieve rapid and accurate detection of disease-related biomarkers.
[0051] Protein array, also known as protein microarray, is a high-throughput biotechnology tool that allows the analysis and study of a large number of proteins at the same time. This technology allows rapid protein expression analysis, protein-protein interaction, protein-small molecule binding studies, etc. by orderly arranging thousands of different protein or protein interaction probes on a solid surface.
[0052] In some embodiments, the product may further include a substance for detecting the expression of CCL3, FOS, IER2, IFITM3, LY6E, MT2A or NFKBIA genes. In some embodiments, the substance for detecting the expression of CCL3, FOS, IER2, IFITM3, LY6E, MT2A or NFKBIA genes may include at least one of a primer pair, a probe or an antibody.
[0053] The term "primer" as used herein refers to a naturally occurring oligonucleotide (e.g., a restriction fragment) or a synthetically produced oligonucleotide that is capable of serving as a starting point for the synthesis of a primer extension product that is complementary to a nucleic acid strand (a template or target sequence) when placed under appropriate conditions (e.g., buffer, salt, temperature, and pH) and in the presence of nucleotides and reagents for nucleic acid polymerization (e.g., a DNA-dependent or RNA-dependent polymerase). Typically, a set of primers will consist of at least two primers, an "upstream primer" and a "downstream primer" that together define an amplicon (a sequence to be amplified using the primers).
[0054] The term "probe" refers to any molecule that can selectively bind to a target biomolecule (e.g., a nucleic acid sequence that hybridizes to the probe). In some embodiments, the probe can be labeled, for example, with a fluorescent group and a quenching group. In some embodiments, the probe can be a Taqman probe with a fluorescent reporter group added to the 5' end and a fluorescent quenching group added to the 3' end.
[0055] Antibodies are proteins with protective effects produced by the body due to antigen stimulation. In some embodiments, antibodies can be used as detection reagents to detect gene expression.
[0056] In some embodiments, the nucleotide sequences of the primer pair for detecting CCL3 may be as shown in SEQ ID NO.3 and SEQ ID NO.4.
[0057] In some embodiments, the nucleotide sequences of the primer pair for detecting FOS may be as shown in SEQ ID NO.5 and SEQ ID NO.6.
[0058] In some embodiments, the nucleotide sequences of the primer pair for detecting IER2 may be as shown in SEQ ID NO.7 and SEQ ID NO.8.
[0059] In some embodiments, the nucleotide sequences of the primer pairs for detecting IFITM3 may be as shown in SEQ ID NO.9 and SEQ ID NO.10.
[0060] In some embodiments, the nucleotide sequence of the primer pair for detecting LY6E may be as shown in SEQ ID NO.13 and SEQ ID NO.14.
[0061] In some embodiments, the nucleotide sequences of the primer pair for detecting MT2A may be as shown in SEQ ID NO.15 and SEQ ID NO.16.
[0062] In some embodiments, the nucleotide sequences of the primer pair for detecting NFKBIA may be as shown in SEQ ID NO.17 and SEQ ID NO.18.
[0063] The present application also discloses a method for determining the stage of Parkinson's disease, wherein the method uses the above-mentioned product to detect the increase in the expression level of at least one gene among JUN or XCL2 genes in the peripheral blood sample of the sample donor relative to that of a healthy person; preferably, the method also includes detecting the increase in the expression level of at least one gene among CCL3, FOS, IER2, IFITM3, LY6E, MT2A or NFKBIA relative to that of a healthy person.
[0064] In some embodiments, the method may include the following steps: (1) extracting genomic DNA of NK cells in a peripheral blood sample to be tested; (2) performing an amplification reaction to obtain the expression level of at least one of the JUN or XCL2 genes in the sample to be tested; preferably, it also includes detecting the expression level of at least one of the CCL3, FOS, IER2, IFITM3, LY6E, MT2A or NFKBIA genes; (3) judging the progression of Parkinson's disease in the patient providing the sample based on the gene expression level.
[0065] The present application also discloses a method for predicting the risk of a subject developing Parkinson's disease, wherein the method uses the above-mentioned product to detect whether the expression level of at least one gene among the JUN or XCL2 genes in the sample to be tested is increased relative to that of a healthy person; preferably, it also includes detecting whether the expression level of at least one gene among CCL3, FOS, IER2, IFITM3, LY6E, MT2A or NFKBIA is increased relative to that of a healthy person.
[0066] In some embodiments, the method may include the following steps: (1) extracting genomic DNA of NK cells in a peripheral blood sample to be tested; (2) performing an amplification reaction to obtain the expression level of at least one gene among JUN or XCL2 genes in the sample to be tested; preferably, it also includes detecting the expression level of at least one gene among CCL3, FOS, IER2, IFITM3, LY6E, MT2A or NFKBIA; (3) predicting the risk of Parkinson's disease in a person corresponding to the sample to be tested based on the gene expression level.
[0067] In some embodiments, the subject can be a mammal, such as a human.
[0068] In some embodiments, the amplification reaction can be a polymerase chain reaction (PCR). In some embodiments, the amplification reaction can be real-time fluorescence quantitative PCR. Polymerase chain reaction (PCR) is a molecular biology technique used to amplify specific DNA fragments. Real-time fluorescence quantitative PCR (Quantitative Real-time PCR), also known as qPCR, is a method for detecting the total amount of products after each polymerase chain reaction (PCR) cycle in a DNA amplification reaction by using fluorescent chemicals. The specific DNA sequence in the sample to be tested can be quantitatively analyzed by internal or external reference methods.
[0069] The term "sample" refers to any composition containing nucleic acid isolated from a subject. In some embodiments, the sample can be selected from at least one of blood, tissue, blood cells, bone marrow, ascites, fine needle biopsy samples, body fluids containing cells, free floating nucleic acids, sputum, saliva, urine, semen, cerebrospinal fluid, peritoneal fluid, pleural fluid, feces, lymph, skin swabs, oral swabs, nasal swabs or lavage. In some embodiments, preferably, the sample can be blood or brain slices. In some embodiments, tissue samples can include fresh tissue samples, formalin-fixed paraffin-embedded tissues (FFPET), etc. In some embodiments, the sample can be fresh or frozen (for example, stored in liquid nitrogen, stored in a refrigerator at -80°C, stored in a refrigerator at -20°C). Fresh samples can be obtained from the subject and then directly processed (for example, RNA extraction, etc.), or the sample can be frozen and stored and then processed when needed.
[0070] This application uses scRNA-seq analysis to find that the differentially expressed cell subpopulation maps in PBMCs of PD patients and healthy people and the differentially expressed genes in NK cells include 6 major immune cell subpopulations, among which NK cells decrease with the progression of PD. This application further clinically verifies the reduction of NK cells in expanded blood samples. They are involved in many immune-related biological processes, and as the disease progresses, NK cells infiltrate into the motor cortex of the brain, demonstrating the close communication between peripheral immune responses and CNS. It is worth noting that XCL2, which is specifically expressed by NK cells, is specifically expressed in NK cell subtypes C2 and C5, and is positively correlated with the severity of PD, and has good predictive performance for PD.
[0071] NK cell-mediated peripheral immune response plays an important role in the pathogenesis of PD, and NK cell-specific XCL2 is expected to become a PD-specific diagnostic marker for the treatment of PD. The indispensable function of NK cells and NK cell-specific molecular markers emphasize the significance of peripheral immune response in the progression of PD.
[0072] The experimental methods in the following examples are conventional methods unless otherwise specified. The experimental materials used in the following examples are purchased from conventional biochemical reagent companies unless otherwise specified. The quantitative tests in the following examples are repeated three times, and the results are averaged.
[0073] The relevant experimental methods in the embodiments of the present invention are as follows:
[0074] 1. Patient Information
[0075] Based on the existing clinical data, we first included 4 PD patients who were diagnosed with different stages of PD from West China Hospital of Sichuan University (Sichuan, China) between September 2017 and March 2018. The inclusion criteria were as follows: clinical diagnosis of early PD (Hoehn-Yahr (HY) stage I-II) or late PD (HY stage III-IV), Unified Parkinson's Disease Rating Scale Part III (UPDRS-III) motor severity score (early PD, 24.96±4.88; late PD, 44.15±4.16), age 60 to 90 years, and stable medication. All patients had no obvious internal diseases, such as tumors, hypertension, diabetes, autoimmune diseases and chronic diseases, as well as psychiatric comorbidities, including mild cognitive impairment (MCI) and dementia. Family history did not show genetic factors. Two age-matched healthy controls who did not suffer from neurodegenerative diseases, neurogenetic diseases, and movement disorders were also included. All participants were informed of the study content and its significance and signed informed consent. Peripheral blood mononuclear cells (PBMCs) were collected from these six participants for single-cell RNA sequencing (scRNA-seq) analysis to obtain cell subpopulations and differential gene information. According to these inclusion criteria and the MedSci sample size calculation method, we then expanded the sample size and collected venous blood from 42 PD patients (28 early cases and 14 late cases) and 14 healthy subjects from September 2017 to January 2021 for fluorescence-activated cell sorting (FACS), its correlation analysis with patients' HY scores, and further PCR testing to verify the changes in differential cell populations and candidate molecule expression in PBMCs of PD patients. In addition, human brain tissue samples from histologically confirmed late-stage PD cases and age-matched healthy individuals without dementia were used. All research procedures involving human subjects were approved by the Clinical Trial and Biomedical Ethics Committee of West China Hospital, Sichuan University (Approval No. 20150236; Chinese Clinical Trial Registration No. ChiCTR1900023975). In addition, this study was conducted in accordance with the guidelines of the Declaration of Helsinki.
[0076] 2. Isolation and Culture of PBMCs
[0077] Patients had their blood drawn at the same time in the morning. PBMCs were stored at 4°C, transported to the laboratory, and isolated and extracted within 4 h. PBMCs were isolated from blood samples of healthy controls and PD patients (PD-early and PD-late) and purified using Ficoll gradient separation (Ficoll-paquetm Plus, GE Healthcare, Sweden). Briefly, 3 mL of Ficoll-Parker gradient was pipetted into two 15 mL centrifuge tubes. Blood samples were diluted with phosphate buffered saline (PBS) in a 1:1 ratio and then layered on the Ficoll-Parker gradient, followed by centrifugation at 400 × g for 30 min. Cells were carefully collected from the interface layer between plasma and Ficoll-Paqueu medium (8 mL / tube) and washed twice in PBS (100 × g for 10 min). After PBMCs were isolated, we immediately cryopreserved the cells using DMEM high glucose medium containing 20% serum and 15% DMSO freezing solution. Cells were counted using a trypan blue hemacytometer and centrifuged at 3 × 10 6 The cells / tube were density frozen in a liquid nitrogen tank.
[0078] 3. 10×Genomics single cell packaging and library preparation
[0079] As described above, the present application used 10×Genomics Chromium Next GEM Single Cell 3′ Reagent Kits v3.1 (10×Genomics, 1000268) to generate single cell libraries according to the manufacturer's protocol (OEbiotech, Shanghai). PBMCs were suspended in 0.04% BSA-PBS and then used II automatic cell counter. This application adjusts the cells to 1×10 6 / mL required concentration. About 13,000 cells were added to each channel to generate nanoscale upgraded gel beads (GEMs) containing barcode information, which were then reverse transcribed in a C1000 Touch Thermal Cycler (Bio-Rad). The amplified cDNA fragments were then cut into 200-300 bp using a Biorrupters sonicator, and conventional second-generation sequencing methods such as linker P5 sequencing and primer R1 sequencing were used. Finally, the DNA library was amplified by PCR.
[0080] 4. Single-cell RNA sequencing
[0081] The library was quantitatively analyzed using Qubit, and qualified libraries were placed in cBot for bridge amplification. The libraries prepared in this study were sequenced on the Illumina Nova 6000PE150 platform. With 150bp paired ends, each library sequenced an entire gene. Four fluorescent group-labeled A, T, G, and C dNTPs were added in each cycle. According to the AT and GC pairing, the corresponding dNTP was bound to the template DNA chain using DNA polymerase, and other unbound dNTPs were washed. When it is removed, the binding position releases a fluorescent signal that can be captured and converted by the computer; in this way, basic information about the binding position is obtained. This application uses the Cell Ranger software pipeline (version 2.2.0) provided by 10×Genomics to demultiplex the cell barcodes, map the read data to the genome and transcriptome using splicing transcripts alignment to a reference sequence (STAR), and down-regulate the sample read data as needed to generate standardized summary data for each sample, thereby generating a matrix of gene counts and cell counts. This application uses the R software package Seurat 20 (Version 2.3.4) Processes unique molecular identifier (UMI) count matrices.
[0082] 5. Quality Control
[0083] To remove low-quality cells and possible multiple captures (which are the main concerns in droplet-based experiments), we filtered cells whose UMI / gene number was more than 4 standard deviations away from the mean and assumed that the UMI / gene number of the cells followed a Gaussian distribution. After visually inspecting the distribution of cells based on the proportion of expressed mitochondrial genes, we further discarded low-quality cells where >10% of the counts belonged to mitochondrial genes. Based on quality control (QC) criteria, 4,8523 single cells (2,475 cells were filtered out of a total of 5,0998 cells) were still included in downstream analysis. The filtered matrix was normalized for library size in Seurat to obtain normalized counts.
[0084] 6. Data processing
[0085] The raw image data files obtained by single-cell RNA sequencing were converted into raw sequences by base calling analysis. The data generated are called raw data or raw reads. These results are stored in FASTQ (.fq) file format, which contains sequence information (reads) and their corresponding sequencing quality information. The most variable genes in single cells were identified using the method described by Macosko et al. Briefly, the average expression and dispersion of each gene were calculated, and then the genes were divided into 12 bins according to the expression. Principal component analysis (PCA) was used to reduce the dimensionality of the logarithmic transformed gene barcode matrix of the top ranked genes. The cells were clustered using a gene-based clustering method and UMAP visualization was performed using “RunUMAP”. The cell type characteristic genes are listed in Table 1. The T cell and NK cell subsets were analyzed using the same method. The likelihood ratio test was used to simultaneously detect the changes in the average expression and the percentage of expressing cells to determine the significant differentially expressed genes (DEGs) between different clusters. The R package SingleR is a novel computational method for unbiased cell type identification in single-cell RNA-seq. It independently infers the cell origin of each single cell and identifies the cell type by referring to the transcriptome datasets "Blueprint Epigenomics" and "Encode". The Pearson correlation between samples was calculated using R (cor(data, method="Pearson")) using the Find Markers function (test.use=MAST). p<0.05 and |log2(fold change)|>0.26 were used as the thresholds for differential expression. Heatmaps, volcano plots, and violin plots were generated using R. The Kyoto Encyclopedia of Genes and Genomes (KEGG) database (https: / / www.kegg.jp / ) was used to analyze the enriched pathways associated with DEGs. Venn diagrams and circular heatmaps were generated using TBtools (https: / / doi.org / 10.1016 / j.molp.2020.06.009).
[0086] Table 1: Characteristic genes of 6 cell subsets
[0087]
[0088]
[0089] 7. Expression distance analysis
[0090] The expression differences between matched subpopulations were determined by the "estimateExpressionShiftMagnitudes()" function in Cacoa. In short, the expression distance between samples was determined as the normalized weighted sum of the relative distances of all cell subpopulations, where the weight was equal to the proportion of the cell subpopulation with the smallest proportion in the two samples compared. The expression distance between samples was projected into a two-dimensional space by a multidimensional scale.
[0091] 8. Gene set scoring analysis
[0092] Gene sets related to "PD" were obtained from the DisGeNET database (https: / / www.disgenet.org / home / ). The transcriptome of each input cell was analyzed by the Seurat function "AddModuleScore" to obtain the gene set score. The changes in scores between different cell groups were analyzed using the ggpubr package by the Wilcoxon test.
[0093] 9. Fluorescence activated cell sorting (FACS)
[0094] PBMCs from 42 PD patients and 14 healthy controls were isolated by flow cytometry to further validate the results of scRNA-seq. Briefly, all PBMCs were washed, counted, and suspended in ice-cold PBS, followed by cell surface antigen staining. Immunofluorescence staining was performed using monoclonal antibodies against CD3, CD45, CD56, CD19 (CD45 / CD56 / CD19 / CD3 detection kit), and CD16 (CD16-PE). Stained cells were analyzed and sorted using BD Biosciences (BD, USA) (T cells (%): CD3 + / All cells except dead cells, B cells (%): CD19 + CD3 - / All cells except dead cells, NK cells (%): CD16 + CD56 + CD3 - / all cells except dead cells), and finally FlowJo (version 10.0) was used to analyze the data. The detailed gating strategy is as follows: 1) Initial gating to exclude dead cells: We used the forward scatter height (FSC-A) and side scatter height (SSC-A) parameters to gate dead cells and obtain region 1 (R1); 2) CD45 + Cell identification: In R1, we selected CD45 (FITC + ) positive cells, producing region 2 (R2); 3) CD45 + CD3+ Isolation of cells (T cells): From R2, we gated out CD45 + CD3 + T cells (PC5 + ), and region 3 (R3) is obtained, representing T cells; 4) CD19 + Isolation of B cells: In R2, we selected CD19 positive cells (ECD) and CD3 negative cells (PC5 - ), and region 4 (R4) was obtained, representing B cells; 5) CD56 + CD16 + Isolation of cells (NK cells): In R2, we selected CD56 + CCD16 + Positive cells (RD1, PE) and CD3 negative cells (PC5 - ), resulting in region 5 (R5) representing NK cells.
[0095] 10. Immunofluorescence staining
[0096] Human PBMC smears and brain tissue sections were prepared for immunofluorescence staining. After the human brain sections were repaired with sodium citrate antigens, they were washed three times with 0.01M PBS for 5 min each time. Then, the cell smears and human brain sections were incubated with 5% goat serum and 0.3% Triton X-100 at room temperature for 2 hours. Then, the primary antibodies (CD16, CD56, rabbit, Bioss, 1:50; TH, rabbit, Abcam, 1:250) diluted with 2% goat serum were added and incubated at 4°C for 18 hours. The negative control was treated with 2% goat serum. After rinsing with PBS three times, the sections were incubated with secondary antibodies (DyLight 488, goat anti-rabbit IgG, Abbkine, 1:400) at room temperature for 3 hours, rinsed with PBS three times, and stained with DAPI. Finally, the sections were sealed with Antifade Mounting Medium (P0126, Beyotime). The fluorescence changes of brain tissue were observed under a light microscope. ImageJ software was used to quantify the green fluorescence channel (positive cells) and the blue fluorescence channel (DAPI) in five randomly selected fields (1.33 mm 2 ) cells. Subsequently, we calculated the positive rate as: (number of positive cells / number of nuclei stained with DAPI) × 100. The TH intensity was measured by ImageJ software, and the TH positive area was normalized to the DAPI positive area (3 sections per group (1.33 mm 2 )).
[0097] 11. Real-time quantitative PCR (RT-qPCR)
[0098] The present application further used RT-qPCR to verify the gene expression differences of 9 key upregulated DEGs in NK cells. Briefly, total RNA was extracted from flow-sorted NK cells using RNAiso plus (TaKaRa, Japan) according to the manufacturer's protocol and purified by Bestar TM qPCR RT Kit (DBI, Germany) was used to reverse transcribe complementary DNA (cDNA). TM RT-qPCR was performed using the Real-Time System (Bio-Rad, USA). The expression levels of the target genes were normalized to the level of GAPDH in each sample. The primer sequences are listed in Table 2.
[0099] Table 2 Primer information of detected genes
[0100]
[0101] 11. Classification of NK cell subtypes in PBMC
[0102] We classified the cell clusters expressing strong signals of GNLY, GZMB, and NKG7 as NK cells. We isolated NK cells for subpopulation identification. The raw UMI counts were normalized with a scaling factor of 10,000 using the “NormalizeData” function in Seurat. Then, the top 3,000 highly variable genes were obtained using the default variance stabilization process using the Seurat function “FindVariableFeatures”. We further integrated the nuclei based on the summarized anchor features using the “IntegrateData” function and performed UMAP visualization after embedding the resulting nuclei into the PCA dimension. According to ElbowPlot and JackStraw, we selected the appropriate dimensionality reduction parameters (dims=20). After multiple “FindClusters” analyses, we selected the most appropriate resolution (resolution=0.2). NK clusters were first classified into major populations based on the expression of two classic functional markers, FCGR3A / CD16 and NCAM1 / CD56. Cluster-specific marker genes were identified using the "FindMarkers()" function in Seurat with the options "logfc.thresh old = 0.25, min.pct = 0.25". P values were corrected by the Bonferroni method, with 0.05 set as the threshold for significance definition. Based on the differences in marker gene expression, they can be divided into different subtypes.
[0103] 12. Statistical analysis
[0104] Sequencing data were analyzed using R software (Version 2.3.4) and Cell Ranger. All data were presented in the form of raw data. SPSS Statistics 25.0 (IBM, Chicago, IL, USA) was used for statistical analysis. The independent sample t test was used for comparison between groups, and one-way analysis of variance (ANOVA) was used for comparison between multiple groups. If the variance was homogeneous, the least significant difference (LSD) result for multiple comparisons was selected; otherwise, Dunnett's T3 test was selected. The Kruskal-Wallis test was used for multiple cluster comparisons that did not meet the traditional homogeneity and variance homogeneity. The clinical efficacy evaluation data of JUN and XCL2 were analyzed using the Kruskal-Wallis test. RT-qPCR results were used for receiver operating characteristic (ROC) curve analysis. Spearman correlation was used to analyze the correlation between the expression levels of JUN and XCL2 and the HY score because they did not meet the normal distribution. The correlation between the percentage of T, B, and NK cells and the severity of PD, as well as the correlation between the number of NK cells and the fluorescence intensity of TH, were analyzed by Pearson correlation because they were in line with the normal distribution. The independent sample t-test was used to exclude the interference of gender. The Venn diagram was drawn using the TBtools (a biologist's toolbox that integrates various biological data processing tools) program (https: / / doi.org / 10.1016 / j.molp.2020.06.009). Using R software, the clusterProfile package was used for KEGG and GO analysis, and the heatmap package was used for heat map analysis. The co-expression of key genes was analyzed by STRING online analysis (https: / / string-db.org / ) and Cytoscape software (https: / / cytoscape.org / ).
[0105] Example 1 - ScRNA-seq analysis of heterogeneity and correlation of PBMC populations
[0106] The detailed procedures in this study are as follows Figure 1 As shown in A. Peripheral blood samples were extracted from healthy controls, patients with early Parkinson's disease (PD-Early) and patients with late Parkinson's disease (PD-Late) for single-cell sequencing (scRNA-seq), and the 10×Genomics platform was used to obtain cell subpopulations and differential gene expression information ( Figure 1A). The number of cells captured in each group was: 8269 cells for sample 16, 7292 cells for sample 17, 13675 cells for sample 19, 9005 cells for sample 20, 4110 cells for sample 25, and 8647 cells for sample 26. After quality control, 48523 cells were finally obtained ( Figure 1 B), and the analysis showed no significant differences in average UMI and average gene count between and within each group. This application performed cluster analysis to study the cellular heterogeneity of cell subpopulations in peripheral blood. Through UMAP visualization, 12 cell clusters of different cell types were annotated and displayed ( Figure 1 C). Based on differential marker gene expression, these 12 clusters were divided into 6 major cell populations: CD4+T cells, CD8+T cells, NK cells, B cells, monocytes, and granulocyte-monocyte progenitor cells (GMP cells) ( Figure 1 D, E).
[0107] To elucidate the relationship between peripheral immune cells and PD risk, we first identified key genes expressed in different types of cells (B cells: CD79A, T cells: CD3D, CD8A, and CD4, monocytes: LYZ, NK cells: GNLY, GMP cells: SOX4) ( Figure 2 A). The expression of differentially expressed genes (DEGs) in these six cell types was then displayed in a heat map (red indicates upregulation, green indicates downregulation) ( Figure 2 B). These DEGs that were upregulated or downregulated during PD progression (healthy-early-late), as well as genes related to PD pathways selected from the GSEA website, were imported into the Venn diagram for intersection analysis. The results showed that there were a large number of intersection DEGs in each cell type, indicating that these DEGs have potential associations with PD risk ( Figure 2 C), these findings emphasize that peripheral immune cells are closely related to PD ( Figure 2 D). We then analyzed the changes in six immune cell types during disease progression. Figure 3 A and B show the comparison of UMAP plots of the changes in the six cell populations in each sample. Overall, the data showed that CD8+T cells and CD4+T cells (in clusters 0, 1, 4, 6, 8, and 10) and NK cells (in cluster 2) had higher cell densities in each sample ( Figure 3 C). In peripheral blood mononuclear cells (PBMCs) of early and late PD individuals, the proportion of NK cells showed a downward trend compared with healthy controls, while the proportion of T cells showed a trend of first increasing and then decreasing compared with healthy controls ( Figure 3 C, D).
[0108] Example 2 - Changes of NK cells and T cells in human peripheral blood and brain during PD progression
[0109] Based on the scRNA-seq results, this application collected PBMCs from 14 healthy controls, 28 early PD patients, and 14 late PD patients to expand the sample inclusion range. First, T cells, B cells, and NK cells were sorted from PBMCs by flow cytometry. CD45 + (FITC + ) cells as the R2 region, from which CD45 + CD3 + Cells are in the R3 region (T cells). From the R2 region, CD19 is recognized + (ECD) and CD3 - Cells (PC5 - ) as the R4 region (B cells), and select CD16 from the R2 region + Cells (PE), CD56 + cells (RD1) and CD3- cells (PC5 - ) as R5 region (NK cells) ( Figure 4 A). The results showed that the proportion of NK cells in PBMCs of PD patients decreased, especially in patients with advanced PD, and the decrease in the proportion of NK cells was significantly negatively correlated with the severity of PD ( Figure 4 AC). The number of B cells did not change significantly in the 3 groups. Although the number of T cells was significantly reduced in patients with advanced PD, the proportion of T cells did not show a significant correlation with the severity of PD in our results ( Figure 4 AC). The significant decrease in the expression of CD16 and CD56 (NK cell marker genes) in PBMCs further demonstrated the reduction of NK cells ( Figure 4 D, E). These findings highlight the potential relevance of NK cells to PD progression, prompting us to consider whether NK cells can infiltrate the brain and affect PD pathology. Therefore, we used human brain tissue sections for further verification. First, the results showed obvious degenerative changes and significant reduction in tyrosine hydroxylase (TH) fluorescence intensity in the amygdala and motor cortex of patients with advanced PD ( Figure 4 F, G). Strikingly, we found NK cells in the amygdala and motor cortex of patients with advanced PD, and the number of NK cells in the motor cortex showed a significant upward trend ( Figure 4 H, I). In addition, the decrease in TH intensity was significantly negatively correlated with the increase in the number of NK cells in the amygdala and motor cortex ( Figure 4 J) These results suggest that NK cells may infiltrate the brain and play an important role in the pathological process of PD.
[0110] Example 3—Bioinformatics analysis reveals that NK cells play an important role in the progression of PD
[0111] The biological functions of NK cells were further explored by bioinformatics analysis. The differentially expressed genes (DEGs) that were continuously upregulated in these NK cells are presented in the heat map ( Figure 5 A). Intersection analysis of upregulated DEGs at different stages screened out a total of 200 key genes ( Figure 5 B). GO analysis showed that the top ten enriched biological process (BP), molecular function (MF), and cellular component (CC) terms involved in these overlapping genes were mostly related to immunity ( Figure 5 C). Among the up-regulated DEGs, more critical genes were further screened by volcano plot and heat map ( Figure 5 D, E). GO analysis showed that these key upregulated DEGs were related to immune regulation and cytokine response ( Figure 5 F), indicating that NK cells may play an important role in the immune regulation of PD. In addition, this application also performed a similar analysis of the downregulated DEGs in NK cells ( Figure 5 G), and screened out 202 genes that were continuously downregulated during the disease process ( Figure 5 H). GO analysis of these DEGs showed that they were mainly related to DNA transcription and signal transduction ( Figure 5 I). KEGG analysis identified that these down-regulated DEGs were significantly involved in the MAPK signaling pathway ( Figure 5 J). The key genes (C5AR1, GNG7, PPBP, CXCR3, PF4, UBR1, FBXO11, TRAF7, KCTD6) identified by PPI analysis can provide a basis for subsequent studies on related functions and screening pathways. Therefore, our subsequent studies mainly focus on NK cells to explore their biomarkers in PD progression.
[0112] Example 4—Identification and verification of PD-related key genes specifically expressed by NK cells
[0113] In view of the abnormal immune response of NK cells in Parkinson's disease, this application screened the differentially expressed genes related to immune pathways and cytokine responses from the above-mentioned upregulated DEGs, aiming to identify the key genes in NK cells that may play an important role in the progression of Parkinson's disease. Excluding genes related to hemoglobin (HBB), cytoskeleton (ACTB), and lymphotoxin (PSME2, LTB) in the blood, this application verified the remaining 9 genes related to signal transduction and immune regulation by RT-qPCR ( Figure 6 A). Among the 9 DEGs, only JUN and XCL2 were significantly upregulated in PD ( Figure 6B). The ROC curve areas (95% confidence interval) of JUN for predicting PD 2.0, PD3.5 and PD were 0.7222 (p = 0.0551), 0.6857 (p = 0.2046) and 0.6080 (p = 0.3242), respectively. The AUCs of XCL-2 for predicting PD were 0.7556 (p = 0.0274), 0.9286 (p = 0.0034) and 0.8040 (p = 0.0055), respectively. This means that the predictive performance of XCL2 is better than that of JUN ( Figure 6 C). In addition, the present application further compared the relative expression of 9 DEGs in males and females and found that except for MT2A, the expression of other genes did not differ significantly between males and females. In addition, the predictive performance of JUN (AUC, 0.5667) and XCL2 (AUC, 0.5635) did not show any significant difference between male and female patients. Therefore, gender differences were not considered in the study design. Analysis of the expression of JUN and XCL2 in different cell populations revealed that JUN was present in B cells, NK cells, and monocytes, while XCL2 was expressed in NK cells and T cells, especially in NK cells where expression increased with disease progression ( Figure 6 D, E). These results suggest that the specific differential expression of XCL2 in NK cells may be a key marker for PD patients. In addition, the correlation analysis between JUN and XCL2 in NK cells showed that XCL2 was significantly positively correlated with the HY score of PD patients ( Figure 6 F, G).
[0114] Example 5 - XCL2, a specific biomarker of NK cell subsets in PD progression
[0115] After re-analyzing the NK cell subsets, the present application finally identified 8 NK cell subsets (C0-C7). The average number of cells in these 8 subsets was 995 (163-2684) ( Figure 7 A). By analyzing the specific marker genes of these 8 subgroups, we found that C2 and C5 subgroups specifically highly expressed XCL2 ( Figure 7 B, C). After normalization of the number of cells, it was found that compared with healthy individuals, the C2 subpopulation increased significantly in the early stage of PD and maintained a high proportion during the progression of the disease; the C5 subpopulation increased slightly in the early stage of PD and increased significantly in the late stage, indicating that XCL2-positive NK cell subpopulations (C2 and C5) are associated with the occurrence and progression of PD ( Figure 7 D). Cell density-based visualization showed that XCL2 was highly enriched in the C2 and C5 subpopulations. In addition, differential gene analysis showed that XCL2 was more highly expressed in the C2 and C5 subpopulations of PD patients compared with healthy individuals ( Figure 7E, F). GO enrichment analysis and enrichment network analysis were further performed on the specific marker genes of C2 and C5 subgroups. We found that the genes with high expression in C2 were mainly related to biological functions such as positive regulation of T cell actvation, interferon-beta production, interferon-gamma production, and chemokine-mediated signaling pathway. The genes with high expression in C5 were mainly related to biological functions such as gamma-delta T cell activation and interleukin-12 production. ( Figure 7 G). XCL2 is involved in these biological functions, further indicating the important function of XCL2 in the occurrence and development of PD and disease-related NK subsets.
[0116] Example 6 - Classification prediction of Parkinson's disease patients using K nearest neighbor classifier
[0117] Single-cell sequencing (scRNA-seq) was used to analyze the differential expression of genes in venous blood mononuclear cells of healthy controls and PD patients at different stages, thereby screening out differentially expressed genes. By comparing sequencing and RT-qPCR results, the XCL2 gene, which has been showing a down-regulated trend, was selected. One gene with the highest prediction accuracy for PD was selected as a candidate characteristic gene for PD, and a prediction model for PD and healthy controls was established. SPSS22.0 (IBM Corp., Armonk, NY, USA) and GraphPad Prism 9 (GraphPad Software, San Diego, California, USA) were used for statistical analysis. The data of each data set were analyzed independently. Since the data were quantitative data and did not conform to the normal distribution, the rank sum test was used for analysis. The binary logistic regression model using the results of RT-qPCR of data sets 1, 2, 3, and 4 as covariates calculated the predicted values, which were then used for ROC curve analysis. All tests were two-tailed, and the significance level was set at P < 0.05.
[0118] Fluorescence quantitative RT-PCR was used to detect the relative expression of XCL2 gene markers in the peripheral blood of 15 PD patients and 9 healthy controls. The PD prediction model was used to classify and predict the above samples. The prediction results were compared with the clinical diagnosis test results of PD to obtain the sensitivity (Sensitivity), specificity (Specificity) and accuracy (Accuracy) of the XCL2 gene marker of the present invention for PD prediction. The Hoehn-Yahr (HY) staging scale can be used to stage PD patients according to their symptoms and severity. The early stage of Parkinson's disease refers to H-Y1~2 stage, the middle stage refers to H-Y3~4 stage, and the late stage refers to H-Y5 stage. The higher the stage, the more serious the disease. In dataset 1, PD2.0 represents the early stage of PD, with 11 patients; in dataset 2, PD3.5 represents the middle stage of PD, with 4 patients; in dataset 3, there are 15 total PD patients, and these three datasets share 9 healthy controls; dataset 4 includes male PD patients (17 cases) and female PD patients (15 cases). These results show that XCL2 is highly expressed in PD patients (including early and middle stages of PD), and both have good diagnostic effects on PD. However, there is no difference in the expression of XCL2 between male and female PD patients, and the AUC curve area is small, indicating that XCL2 diagnosis of PD is not affected by gender; the specific test results are shown in Table 3 and ROC curve diagram Figure 8 , Fig. 9 , Fig.10 and Fig.11 .
[0119] Table 3
[0120]
[0121] Results Analysis
[0122] This application preliminarily mapped the peripheral immune map of PD patients through scRNA-seq technology, and defined specific diagnostic markers for PD, including 6 major immune cell subsets: T cells (CD4+, CD8+), B cells, NK cells, monocytes and GMP, showing the changes in cell subsets and different gene expression patterns during the progression of PD. This application further expanded the sample size and found through clinical validation that among these cell subsets, NK cells are involved in many immune-related biological processes, and their levels in blood samples are significantly reduced as PD progresses. As the disease progresses, NK cells infiltrate the motor cortex of the brain, proving that there is close communication between peripheral immune responses and the central nervous system. NK cell-specific XCL2 is specifically expressed in NK cell subsets C2 and C5, and may become a specific diagnostic marker for PD.
[0123] In this application, the present application constructed the peripheral blood immune map of PD patients, revealing the changes in cell subsets in the peripheral blood of PD patients, indicating that with the progression of PD, the number of NK cells decreased and participated in immune-related biological processes. The disease-related risk score showed that NK cells were correlated with PD, and the PD risk genes present in NK cells were also related to immune regulation. These results suggest that abnormal changes in NK cells lead to peripheral blood immune dysregulation in PD patients, thereby aggravating the severity of the disease. The results of this application emphasize the important role of NK cells in the progression of Parkinson's disease. The results of the study on NK cells in PD patients also showed enrichment in mitochondrial-related pathways. ATP produced by mitochondria is an important energy source for maintaining the function of neurons and immune cells. According to previous reports, dopaminergic neurons in PD patients often show mitochondrial dysfunction, resulting in insufficient energy metabolism and increased oxidative stress, exacerbating neuronal damage. In an inflammatory state, the activation and proliferation of immune cells require a lot of energy, and mitochondria meet this demand through metabolic adaptation. At the same time, changes in energy supply may affect the function and survival of neurons, thereby affecting neuroimmune inflammatory responses. Our research results consistently highlight the key role of NK cells in the progression of PD.
[0124] There is a close connection between peripheral immune responses and the CNS. NK cells infiltrate the brain in neurodegenerative diseases such as Alzheimer's disease (AD) and PD, and regulate the expression of peripheral NK cell immune-related genes, which can promote the infiltration of NK cells in the brain and neuroinflammatory changes in AD. At the same time, studies on animal models of PD driven mainly by α-synuclein (α-syn) have shown that infiltrated NK cells are involved in the inflammatory process and substantia nigra neurodegeneration, because the removal of these cell components affects the survival of neurons. This application shows that peripheral blood NK cells can enter the motor cortex of the brain and participate in the pathogenesis of Parkinson's disease. This application speculates that during the progression of PD, the integrity of the blood-brain barrier is impaired, resulting in the recruitment of peripheral innate immune cells by activated innate immune cells (including microglia and astrocytes) in the brain. These results suggest that NK cells are involved in the deterioration of the immune environment of the central nervous system in the peripheral immune system. In addition, it is well known that PD patients have obvious characteristic motor symptoms, such as bradykinesia and muscle rigidity, which are closely related to the motor cortex of the brain. This application uses advanced PD human brain samples to show that peripheral NK cells may infiltrate the motor cortex and amygdala of the brain, potentially participating in the pathogenesis of Parkinson's disease. Recent studies have reported that motor cortex thinning and amygdala volume reduction are evident in severe Parkinson's disease. These morphological changes are associated with increased duration of the disease and severity of motor symptoms, which may have an impact on future PD progression. Further verification and in-depth exploration of the mechanisms of NK cells in a larger group of clinical subjects is a necessary step to promote PD research. Current research on Parkinson's disease focuses on dopamine neurons and whether the motor cortex is also involved, which will help further study the progression of Parkinson's disease.
[0125] In addition, this application attempts to explore cell-specific immune-related biomarkers that are specifically expressed in NK cells during the progression of PD. The specific differential expression of XCL2 in NK cells has a good predictive effect on different stages of PD, and is significantly positively correlated with the severity of the disease in PD patients. On this basis, the application further analyzed the subpopulations of NK cells and was surprised to find that as the severity of PD increased, the expression level of XCL2 in NK cell subpopulations C2 and C5 increased significantly. This observation suggests that NK cell subtypes C2 and C5 may be the main cell types infiltrating the brain in PD and may be involved in immune responses in the brain. Further research can explore the exact functions and mechanisms of these specific NK cell subtypes in the pathogenesis of PD. As mentioned above, XCL2 transcripts are closely related to the gene signature of NK cells and are associated with the overall survival of cancer patients. At present, few studies have clarified the characteristics of NK cell-specific XCL2 expression in the occurrence and development of PD. It has been reported that human NK cells can produce chemokines CCL5, XCL1, and XCL2, but under steady-state conditions, the latter two are rare sources in the blood, which may explain the abnormal upregulation of XCL2 in peripheral blood NK cells as PD progresses. These studies reveal key features of peripheral immune responses in the onset and progression of PD and identify NK cell populations with specific gene expression programs.
[0126] In summary, this application has mapped the peripheral immune profile of Parkinson's disease patients through scRNA-seq, revealing the changing patterns of cell subpopulations and different gene expressions during the progression of Parkinson's disease. In addition, as the disease progresses, the infiltration of NK cells in the motor cortex of the brain indicates a close connection between peripheral immune responses and the CNS. It is worth noting that the NK cell-specific XCL2-specific expression is positively correlated with the severity of PD and has good predictive performance for PD, which will provide better clues and therapeutic targets for the future treatment of PD.
[0127] The basic concepts have been described above. Obviously, for those skilled in the art, the above detailed disclosure is only for example and does not constitute a limitation of this specification. Although not explicitly stated here, those skilled in the art may make various modifications, improvements and corrections to this specification. Such modifications, improvements and corrections are suggested in this specification, so such modifications, improvements and corrections still belong to the spirit and scope of the exemplary embodiments of this specification.
[0128] At the same time, this specification uses specific words to describe the embodiments of this specification. For example, "one embodiment", "an embodiment", and / or "some embodiments" refer to a certain feature, structure or characteristic related to at least one embodiment of this specification. Therefore, it should be emphasized and noted that "one embodiment" or "an embodiment" or "an alternative embodiment" mentioned twice or more in different positions in this specification does not necessarily refer to the same embodiment. In addition, certain features, structures or characteristics in one or more embodiments of this specification can be appropriately combined.
[0129] In some embodiments, numbers describing the number of components and attributes are used. It should be understood that such numbers used in the description of the embodiments are modified by the modifiers "about", "approximately" or "substantially" in some examples. Unless otherwise specified, "about", "approximately" or "substantially" indicate that the numbers are allowed to vary by ±20%. Accordingly, in some embodiments, the numerical parameters used in the specification and claims are approximate values, which may change according to the required features of individual embodiments. In some embodiments, the numerical parameters should take into account the specified significant digits and adopt the general method of retaining digits. Although the numerical domains and parameters used to confirm the breadth of their range in some embodiments of this specification are approximate values, in specific embodiments, the setting of such numerical values is as accurate as possible within the feasible range.
[0130] Finally, it should be understood that the embodiments described in this specification are only used to illustrate the principles of the embodiments of this specification. Other variations may also fall within the scope of this specification. Therefore, as an example and not a limitation, alternative configurations of the embodiments of this specification may be considered consistent with the teachings of this specification. Accordingly, the embodiments of this specification are not limited to the embodiments explicitly introduced and described in this specification.
Claims
1. Use of a substance for detecting JUN and / or XCL2 gene expression in the preparation of a product for detecting Parkinson's disease.
2. The use according to claim 1, characterized in that The sample tested by the product is peripheral blood. Furthermore, the product is used to detect the expression level of JUN and / or XCL2 genes in NK cells of peripheral blood; the product for detecting Parkinson's disease is selected from a Parkinson's disease progression detection product or a Parkinson's disease risk assessment product.
3. The use according to claim 1, characterized in that The substance for detecting the expression of JUN or XCL2 gene includes at least one of a primer pair, a probe or an antibody; And / or, the product is any one of a kit, a chip, a membrane strip, a protein array, a composition or a detection system. Preferably, the product includes one or more of a DNA polymerase, a deoxynucleotide (dNTP) mixture, a buffer solution, a positive control or a negative control.
4. The use according to claim 1, characterized in that The nucleotide sequences of the primer pair for detecting JUN are shown in SEQ ID NO.11 and SEQ ID NO.12; And / or, the nucleotide sequences of the primer pair for detecting XCL2 are shown as SEQ ID NO.19 and SEQ ID NO.
20.
5. The use according to claim 1, characterized in that The product also includes a substance for detecting the expression of CCL3, FOS, IER2, IFITM3, LY6E, MT2A or NFKBIA genes, and the substance for detecting the expression of CCL3, FOS, IER2, IFITM3, LY6E, MT2A or NFKBIA genes includes at least one of a primer pair, a probe or an antibody.
6. The use according to claim 1, characterized in that The method of using the product comprises the following steps: (1) extracting genomic DNA of NK cells from a peripheral blood sample to be tested; (2) performing an amplification reaction to obtain the expression level of at least one of the JUN or XCL2 genes in the sample to be tested; preferably, the method further comprises detecting the expression level of at least one of the CCL3, FOS, IER2, IFITM3, LY6E, MT2A or NFKBIA genes; (3) judging the progression of Parkinson's disease in the patient providing the sample based on the gene expression level.
7. The use according to claim 6, characterized in that The nucleotide sequences of the primer pair for detecting JUN are shown in SEQ ID NO.11 and SEQ ID NO.12; and / or, the nucleotide sequences of the primer pair for detecting XCL2 are shown in SEQ ID NO.19 and SEQ ID NO.20; and / or, the nucleotide sequences of the primer pair for detecting FOS are shown in SEQ ID NO.5 and SEQ ID NO.6; and / or, the nucleotide sequences of the primer pair for detecting IER2 are shown in SEQ ID NO.7 and SEQ ID NO.8; And / or, the nucleotide sequences of the primer pair for detecting IFITM3 are shown in SEQ ID NO.9 and SEQ ID NO.10; and / or, the nucleotide sequences of the primer pair for detecting LY6E are shown in SEQ ID NO.13 and SEQ ID NO.14; and / or, the nucleotide sequences of the primer pair for detecting MT2A are shown in SEQ ID NO.15 and SEQ ID NO.16; And / or, the nucleotide sequences of the primer pair for detecting NFKBIA are shown as SEQ ID NO.17 and SEQ ID NO.
18.
8. A product for detecting Parkinson's disease, comprising a substance for detecting JUN and / or XCL2 gene expression.
9. The product according to claim 8, characterized in that The sample tested by the product is peripheral blood. Furthermore, the product is used to detect the expression level of JUN and / or XCL2 genes in NK cells of peripheral blood; the product for detecting Parkinson's disease is selected from a Parkinson's disease progression detection product or a Parkinson's disease risk assessment product.
10. The product according to claim 8, characterized in that The substance for detecting the expression of JUN or XCL2 gene includes at least one of a primer pair, a probe or an antibody; And / or, the product is any one of a kit, a chip, a membrane strip, a protein array, a composition or a detection system. Preferably, the product includes one or more of a DNA polymerase, a deoxynucleotide (dNTP) mixture, a buffer solution, a positive control or a negative control.
11. The product according to claim 10, characterized in that Preferably, the nucleotide sequences of the primer pair for detecting JUN are shown in SEQ ID NO.11 and SEQ ID NO.12; And / or, the nucleotide sequences of the primer pair for detecting XCL2 are shown as SEQ ID NO.19 and SEQ ID NO.
20.
12. The product according to claim 8, characterized in that The product also includes a substance for detecting the expression of CCL3, FOS, IER2, IFITM3, LY6E, MT2A or NFKBIA genes, and the substance for detecting the expression of CCL3, FOS, IER2, IFITM3, LY6E, MT2A or NFKBIA genes includes at least one of a primer pair, a probe or an antibody.
13. The product according to claim 12, characterized in that The nucleotide sequences of the primer pair for detecting CCL3 are shown in SEQ ID NO.3 and SEQ ID NO.4; And / or, the nucleotide sequences of the primer pair for detecting FOS are shown in SEQ ID NO.5 and SEQ ID NO.6; And / or, the nucleotide sequences of the primer pair for detecting IER2 are shown in SEQ ID NO.7 and SEQ ID NO.8; And / or, the nucleotide sequences of the primer pair for detecting IFITM3 are shown in SEQ ID NO.9 and SEQ ID NO.10; And / or, the nucleotide sequences of the primer pair for detecting LY6E are shown in SEQ ID NO.13 and SEQ ID NO.14; And / or, the nucleotide sequence of the primer pair for detecting MT2A is shown as SEQ ID NO.15 and SEQ ID NO.16; and / or, the nucleotide sequence of the primer pair for detecting NFKBIA is shown as SEQ ID NO.17 and SEQ ID NO.18.
Citation Information
Patent Citations
Method for inhibiting microglial cell activation
CN118414355A
IVIG modulation of chemokines for treatment of multiple sclerosis, alzheimer's disease, and parkinson's disease
US20090148463A1
Non-coding RNAS (NCRNA) for the diagnosis of cognitive disorders
US20210071252A1
